AGENDA |
Friday – April 15, 2011
|
7.30 AM
|
Registration & breakfast
|
|
8.00 AM
|
Welcome and introduction
Mohammad Jahanzeb, MD, FACP
|
Session I: Lung Cancer/Head and Neck Cancer—Moderator Luis Raez, MD, FACP
|
8.05 AM
|
Incorporating genomic tests in decision making
Fadlo Khuri, MD
|
|
8.30 AM
|
Targeted therapy in lung cancer
Roman Perez-Soler, MD
|
|
8.55 AM
|
Multidisciplinary approach to lung cancer
Thomas D'Amico, MD
|
|
9.20 AM
|
Clinical case: Tailoring front-line therapy for advanced non-small cell lung cancer (NSCLC)
Roman Perez-Soler, MD
|
|
9.40 AM
|
BREAK
|
|
10.00 AM
|
Clinical case: Second-line therapy for advanced NSCLC
Merrill Kies, MD
|
|
10.20 AM
|
Debate: Is the role of surgery decreasing in head and neck cancer?
Yes: Fadlo Khuri, MD
No: W. Jarrard Goodwin, MD, FACS
|
|
10.30 AM
|
Debate: Should every responding or stable patient with advanced NSCLC be offered maintenance therapy?
Yes: Roman Perez-Soler, MD
No: Merrill Kies, MD
|
Session II: Gastrointestinal Cancer—Moderator: Reshma Mahtani, DO
|
10.40 AM
|
Incorporating genomic tests in decision making
Ramesh Ramanathan, MD
|
|
11.05 AM
|
Targeted therapy in GI cancers
Zev Wainberg, MD, MSc
|
|
11.30 AM
|
Multidisciplinary approach to GI cancer
Bruce Minsky, MD
|
|
11.55 AM
|
LUNCH
|
|
12.55 PM
|
Clinical case: Metastatic colorectal cancer
Zev Wainberg, MD, MSc
|
|
1.15 PM
|
Clinical case: Metastatic gastric cancer
Ramesh Ramanathan, MD
|
|
1.35 PM
|
Debate: Should all gastric cancer patients have HER2 testing?
Yes: Ramesh Ramanathan, MD
No: Zev Wainberg, MD, MSc
|
|
1.45 PM
|
Adjourn
|
Saturday – April 16, 2011
|
7.30 AM
|
Registration & breakfast
|
|
8.00 AM
|
Welcome and introduction
Mohammad Jahanzeb, MD, FACP
|
Session III: Breast Cancer—Moderator: Orlando E. Silva, MD, JD, FACP, FCLM
|
8.05 AM
|
Incorporating genomic tests in decision making
Susana Campos, MD, MPH
|
|
8.30 AM
|
Targeted therapy in breast cancer
Mary Cianfrocca, DO
|
|
8.55 AM
|
Multidisciplinary approach to breast cancer
Terry Mamounas, MD, MPH, FACS
|
|
9.20 AM
|
Clinical case: HER2-positive metastatic breast cancer
Susana Campos, MD, MPH
|
|
9.40 AM
|
BREAK
|
|
10.00 AM
|
Clinical case: Recurrent triple-negative breast cancer
Ruth O'Regan, MD
|
|
10.20 AM
|
Debate: Should every patient with a positive sentinel lymph node undergo axillary dissection?
Yes: Terry Mamounas, MD, MPH, FACS
No: Ruth O'Regan, MD
|
|
10.30 AM
|
Debate: Should all postmenopausal HER2-positive/ER-positive patients receive combination of an aromatase inhibitor and HER2 blockade?
Yes: Susana Campos, MD, MPH
No: Ruth O'Regan, MD
|
Session IV: Prostate Cancer—Moderator: Bruce Kava, MD, FACS
|
10.40 AM
|
Targeted therapy in prostate cancer
Philip Kantoff, MD
|
|
11.05 AM
|
Multidisciplinary approach to prostate cancer
Mark Soloway, MD
|
|
11.30 AM
|
LUNCH
|
|
12.30 PM
|
Clinical case: Hormone-responsive prostate cancer (HRPC)
Philip Kantoff, MD
|
|
12.50 PM
|
Clinical case: Castration-resistant prostate cancer
Matthew R. Smith, MD, PhD
|
|
1.10 PM
|
Debate: Are all taxanes equivalent in the treatment of HRPC?
Yes: Matthew R. Smith, MD, PhD
No: Robert Fine, MD
|
|
1.20 PM
|
Debate: Is immunotherapy the choice systemic therapy for the future?
Yes: Philip Kantoff, MD
No: Mark Soloway, MD
|
1.30 PM
|
Closing remarks
|
|
1.35 PM
|
Adjourn
|
|
 CHAIRMAN
Mohammad Jahanzeb, MD, FACP
Sylvester Comprehensive Cancer Center
University of Miami
Deerfield Beach, Florida
FACULTY
Susana Campos, MD, MPH
Dana-Farber Cancer Institute
Boston, Massachusetts
Mary Cianfrocca, DO
Northwestern University
Chicago, Illinois
Thomas D'Amico, MD
Duke University Medical Center
Durham, North Carolina
Robert Fine, MD
Columbia University
New York, New York
W. Jarrard Goodwin, MD, FACS
University of Miami
Deerfield Beach, Florida
Philip Kantoff, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
Bruce Kava, MD, FACS
University of Miami
Deerfield Beach, Florida
Fadlo Khuri, MD
Emory University
Atlanta, Georgia
Merrill Kies, MD
M. D. Anderson Cancer Center
Houston, Texas
Reshma Mahtani, DO
Sylvester Comprehensive Cancer Center
University of Miami
Deerfield Beach, Florida
|
Terry Mamounas, MD, MPH, FACS
Aultman Cancer Center
Canton, Ohio
Bruce Minsky, MD
University of Chicago Medical Center
Chicago, Illinois
Roman Perez-Soler, MD
Albert Einstein Cancer Center
New York, New York
Ramesh Ramanathan, MD
The Translational Genomics Research Institute
Phoenix, Arizona
Luis Raez, MD, FACP
University of Miami
Miami, Florida
Ruth O'Regan, MD
Emory University
Atlanta, Georgia
Orlando E. Silva, MD, JD, FACP, FCLM
Leonard M. Miller School of Medicine
University of Miami
Miami, Florida
Matthew R. Smith, MD, PhD
Harvard Medical School
Boston, Massachusetts
Mark Soloway, MD
University of Miami
Miami, Florida
Zev Wainberg, MD, MSc
University of California – Los Angeles
Jonsson Comprehensive Cancer Center
Los Angeles, California |
|
PHYSICIAN LEARNING OBJECTIVES |
After successful completion of this continuing medical education activity, participants should be able to:
- Discuss challenging issues in the management of patients with head and neck cancer, metastatic colorectal cancer, gastric cancer, breast cancer, prostate cancer, and NSCLC
- Describe strategies for the integration of novel agents in the management of patients with these solid tumors with attention to clinical and molecular determinants, disease stage, comorbidities, tolerability, and other criteria for therapy selection
- Integrate multimodality treatment strategies—including radiation therapy, chemotherapy, and targeted therapy—into the management of patients with head and neck cancer, colorectal cancer, prostate cancer, breast cancer, and lung cancer, when warranted
|
NURSE LEARNING OBJECTIVES | After successfully completing this educational program, the nurse will be able to:
- Describe challenging issues in the management of patients with head and neck cancer, metastatic colorectal cancer, gastric cancer, breast cancer, prostate cancer, and non-small cell lung cancer.
- Describe current treatment options treatment options including using a multidisciplinary approach for the treatment of patients with head & neck cancer, metastatic colon cancer, breast cancer, prostate cancer and non-small cell lung cancer.
- Describe genomic testing in decision making for lung, breast and neck and breast cancer
Nursing CEUs will be provided by:
University of Miami Hospital & Clinics
1475 N.W. 12 Avenue
Miami, Florida 33136
Florida Board of Nursing Provider Number: 50-2900
|
DISCLOSURE OF CONFLICTS OF INTEREST | prIME Oncology assess conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. |
REGISTRATION INFORMATION | The registration fee includes all activity materials, continental breakfast, lunch, and refreshment breaks.
Physicians
- Preregistration: $100.00
- Onsite registration: $150.00
Midlevel
- Preregistration: $75.00*
- Onsite registration: $125.00*
Nurses
- Preregistration: $40.00*
- Onsite registration: $60.00*
*Supporting documentation of eligibility may be required.
Residents/Fellows
Residents and fellows are eligible for complimentary registration. Please contact brittany.brown@oncoservices.com for more information.
ONS Members
ONS members are eligible for discounted registration rates. Please email brittany.brown@oncoservices.com with the name of your ONS chapter for more information.
Preregistration will close Tuesday, April 12, 2011. After preregistration closes, the price will increase to the onsite rate. *Attendees may still register onsite the morning of the meeting.
The registration fee is nonrefundable. Substitutions will be accepted up to one week prior to the meeting date with written notice.
The registration fee includes all activity materials, breakfast and refreshment breaks. prIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.
|
|
|
|
Venue & Accommodations | W Fort Lauderdale
401 North Fort Lauderdale Beach Boulevard
Fort Lauderdale, Florida 33304
United States
Tel: 954.414.8200
www.whotels.com/fortlauderdale
Hotel reservations must be made directly with the W Fort Lauderdale Hotel by calling 954.414.8200. Please advise that you are with the 12th Annual Palm Beach Cancer Symposium. The conference room rate is $239/night plus applicable taxes, currently at 11%. All reservations must be confirmed with a major credit card. Reservations must be made by March 15, 2011. After March 15, 2011, rooms will be provided on a space-available basis at the standard rate.
|
TARGET AUDIENCE |
This educational activity is designed for medical oncologists, surgeons, radiation oncologists and other healthcare providers involved and/or interested in the diagnosis, treatment, and management of patients with solid tumors.
|
CONTINUING MEDICAL EDUCATION | prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this live educational activity for a maximum of 8.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
|
SPONSORSHIP |
This activity is sponsored by prIME Oncology.
|
SUPPORT |
Supported by educational grants from Amgen Inc.; Bristol-Meyers Squibb; Dendreon Corporation; Eisai, Inc.; Genentech, Inc.; Genomic Health; Morphotek, Inc.; and sanofi-aventis, U.S.
Financial support opportunities are available to companies interested in supporting this activity. For more information, please contact Shahara Dunlop at 678.892.1340 or shahara.dunlop@prIMEoncology.org. |
|
